Corcept Therapeutics Newsroom

Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating

Futu NewsNov 4 20:35

Truist Financial Keeps Their Buy Rating on Corcept Therapeutics (CORT)

TipRanksNov 4 20:18

A Quick Look at Today's Ratings for Corcept Therapeutics(CORT.US), With a Forecast Between $67 to $80

Futu NewsOct 31 21:20

Corcept Therapeutics Analyst Ratings

BenzingaOct 31 19:18

Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating

Futu NewsOct 21 19:34

H.C. Wainwright Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $80

Futu NewsOct 18 18:31

Corcept Therapeutics Is Maintained at Buy by Truist Securities

Dow JonesSep 30 22:19

Corcept Therapeutics Analyst Ratings

BenzingaSep 30 22:09

Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Announces Target Price $76

Futu NewsSep 30 19:33

CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $78

Futu NewsSep 25 20:34

Buy Rating Affirmed for Corcept Therapeutics Amid Strong Financials and Promising Clinical Trials

TipRanksSep 25 19:37

Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating

Futu NewsSep 20 19:34

Truist Financial Gives a Buy Rating to Corcept Therapeutics (CORT)

TipRanksSep 20 19:30

Corcept Therapeutics Is Maintained at Overweight by Piper Sandler

Dow JonesSep 19 01:38

Corcept Therapeutics Analyst Ratings

BenzingaSep 19 01:28

Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $67

Futu NewsSep 18 23:31

CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $78

Futu NewsAug 15 19:34

Buy Rating Affirmed for Corcept Therapeutics on Strong Financials and Promising Drug Pipeline

TipRanksAug 15 19:10

Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $78

BenzingaJul 31 20:36

CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $78

Futu NewsJul 31 19:43